$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416083497 Filed on February 22, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2014 Q4
Revenue	$379.0K	$134.0K	$367.0K
YoY Change	8.6%	-63.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.400M	$1.680M	$1.300M
YoY Change	96.72%	29.23%	23.81%
% of Gross Profit
Research & Development	$1.048M	$704.0K	$731.0K
YoY Change	28.59%	-3.69%	24.96%
% of Gross Profit
Depreciation & Amortization	$261.0K	$1.000K	$90.00K
YoY Change	2272.73%	-98.89%	0.0%
% of Gross Profit
Operating Expenses	$3.451M	$2.388M	$2.033M
YoY Change	69.42%	17.46%	24.27%
Operating Profit	-$3.072M	-$2.254M	-$1.666M
YoY Change	81.99%	35.29%	1.83%
Interest Expense	$323.0K	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$313.0K	$8.000K	$13.00K
YoY Change	-2945.45%	-38.46%	18.18%
Pretax Income	-$3.390M	-$2.250M	-$1.650M
YoY Change	101.79%	36.36%	1.23%
Income Tax
% Of Pretax Income
Net Earnings	-$3.036M	-$2.246M	-$1.653M
YoY Change	81.04%	35.87%	1.41%
Net Earnings / Revenue	-801.06%	-1676.12%	-450.41%
Basic Earnings Per Share
Diluted Earnings Per Share	-$374.4K	-$291.1K	-$232.4K
COMMON SHARES
Basic Shares Outstanding	82.61M shares	77.33M shares	71.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q4	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.89M	$6.730M	$7.360M
YoY Change	170.92%	-8.56%	29.58%
Cash & Equivalents	$21.89M	$6.732M	$7.363M
Short-Term Investments
Other Short-Term Assets	$320.0K	$250.0K	$280.0K
YoY Change	6.67%	-10.71%	7.69%
Inventory	$60.00K
Prepaid Expenses
Receivables	$450.0K	$202.0K	$920.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.72M	$7.201M	$8.560M
YoY Change	151.22%	-15.88%	23.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.78M	$14.00K	$20.00K
YoY Change	184007.14%	-30.0%	300.0%
Goodwill
YoY Change
Intangibles	$2.139M	$2.201M
YoY Change	-10.43%
Long-Term Investments
YoY Change
Other Assets	$30.00K
YoY Change
Total Long-Term Assets	$27.95M	$2.215M	$2.480M
YoY Change	1063.41%	-10.69%	-7.39%
TOTAL ASSETS
Total Short-Term Assets	$22.72M	$7.201M	$8.560M
Total Long-Term Assets	$27.95M	$2.215M	$2.480M
Total Assets	$50.67M	$9.416M	$11.04M
YoY Change	342.64%	-14.71%	14.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.551M	$1.334M	$980.0K
YoY Change	90.31%	36.12%	-21.6%
Accrued Expenses	$650.0K	$188.0K	$490.0K
YoY Change	60.49%	-61.63%	16.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$170.0K
YoY Change
Total Short-Term Liabilities	$2.441M	$1.540M	$1.480M
YoY Change	95.28%	4.05%	-11.06%
LONG-TERM LIABILITIES
Long-Term Debt	$25.31M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$25.31M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.441M	$1.540M	$1.480M
Total Long-Term Liabilities	$25.31M	$0.00	$0.00
Total Liabilities	$27.75M	$1.538M	$1.480M
YoY Change	2112.84%	3.92%	-10.84%
SHAREHOLDERS EQUITY
Retained Earnings		-$51.88M
YoY Change
Common Stock	$63.21M	$59.79M
YoY Change	12.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.270M	$7.878M	$9.570M
YoY Change
Total Liabilities & Shareholders Equity	$50.67M	$9.416M	$11.04M
YoY Change	342.69%	-14.71%	14.76%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2014 Q4
OPERATING ACTIVITIES
Net Income	-$3.036M	-$2.246M	-$1.653M
YoY Change	81.04%	35.87%	1.41%
Depreciation, Depletion And Amortization	$261.0K	$1.000K	$90.00K
YoY Change	2272.73%	-98.89%	0.0%
Cash From Operating Activities	-$2.440M	-$1.660M	-$1.620M
YoY Change	83.46%	2.47%	24.62%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$10.00K	-$70.00K
YoY Change	-100.0%	-114.29%	250.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$10.00K	-$70.00K
YoY Change	-100.0%	-114.29%	250.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.60M	0.000	5.580M
YoY Change	742.11%	-100.0%	57.18%
NET CHANGE
Cash From Operating Activities	-2.440M	-1.660M	-1.620M
Cash From Investing Activities	0.000	10.00K	-70.00K
Cash From Financing Activities	17.60M	0.000	5.580M
Net Change In Cash	15.16M	-1.650M	3.890M
YoY Change	2035.21%	-142.42%	74.44%
FREE CASH FLOW
Cash From Operating Activities	-$2.440M	-$1.660M	-$1.620M
Capital Expenditures	$0.00	$10.00K	-$70.00K
Free Cash Flow	-$2.440M	-$1.670M	-$1.550M
YoY Change	90.63%	7.74%	21.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	77000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	77000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59006000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59712000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47827000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51878000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	11231000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	7878000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12494000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	182000	USD
CY2015Q4	us-gaap	Assets Assets	9416000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	445000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	7201000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1334000	USD
CY2015Q2	us-gaap	Assets Assets	12494000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	159000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1104000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	202000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	10121000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2360000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6732000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2201000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	252000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	134000	USD
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	704000	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1684000	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	2388000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2254000	USD
CY2015Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9494000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	188000	USD
CY2014Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70957000	shares
CY2015Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2245000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	63000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	867000	USD
CY2014Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1664000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	338000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5212000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9416000	USD
CY2015Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	15000	USD
CY2015Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2015Q4	us-gaap	Liabilities Liabilities	1538000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	1263000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	294000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1186000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1255000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1916000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3106000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2352000	USD
	us-gaap	Operating Expenses OperatingExpenses	4361000	USD
	us-gaap	Operating Expenses OperatingExpenses	4268000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4067000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3082000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	12000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	15000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4051000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3063000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4059000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3077000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	77316000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68408000	shares
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	367000	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	731000	USD
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1302000	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	2033000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1666000	USD
CY2014Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2015Q4	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	6000	USD
CY2014Q4	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	10000	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-2246000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-1653000	USD
CY2015Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	USD
CY2014Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000	USD
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	77326000	shares
	ibio	Common Stock Issued For Warrant Exercises Value CommonStockIssuedForWarrantExercisesValue	63000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	643000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	643000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	466000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	182000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	178000	USD
	us-gaap	Depreciation Depreciation	2000	USD
	us-gaap	Depreciation Depreciation	2000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-243000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	379000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	70000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	160000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	190000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	664000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	29000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	407000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2814000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2193000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	85000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-100000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6079000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.38
CY2015Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	12100000	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.53
CY2015Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	120000	shares
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2246000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1653000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4051000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3063000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-6000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-13000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2762000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3773000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3590000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7363000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	40000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	23000	USD
	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	0	USD
	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	-12000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	15000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	ibio	Long Term Purchase Commitment Expire Date LongTermPurchaseCommitmentExpireDate	2015-12-31
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	15000000	shares
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2201000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2360000	USD
CY2015Q4	ibio	Registration Common Stock RegistrationCommonStock	15000000	USD
	ibio	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	120000	shares
	ibio	Class Of Warrants Or Rights Expired ClassOfWarrantsOrRightsExpired	4699324	shares
	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.53
	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	2.09
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6633324	shares
CY2014Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	9700000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	643000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	466000	USD
CY2015Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	314000	USD
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	213000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2900000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9523334	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2550000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12073334	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12010937	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7413357	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.22
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.72
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.32
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.32
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.32
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1848000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	461000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	460000	USD
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	404000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1217	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.63
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2100000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-17000	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-30000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5298000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5281000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3097000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2921000	USD
CY2015Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	178000	USD
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	153000	USD
CY2015Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2015Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77325410	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77325410	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77205410	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77205410	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0213	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription	Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million.
CY2015Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	1875000	USD
CY2015Q4	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	252000	USD
CY2014Q4	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	258000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	478000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	480000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="center"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> 1.</b></font></div> </td> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Nature of Business</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies - the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods, and reduced production time, capital and operating costs for biopharmaceuticals.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBioDefense Biologics LLC (“iBioDefense”) iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense has not commenced any activities to date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio Peptide Therapeutics LLC (“iBio Peptide”) iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide has not commenced any activities to date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/FioCruz (“FioCruz”) beyond the current Yellow Fever Vaccine program (see Note 6) and development of biosimilar products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio CMO LLC (“iBio CMO”) iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned 100% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $15 million in cash for a 30% interest in iBio CMO. The Company retained a 70% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technology for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technology.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio CMO’s operations will take place in Bryant, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000 square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a 35-year sublease for the facility (see Note 12). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-17000	USD
CY2014Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-30000	USD
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1800000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	6600000	shares
CY2015Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91000	USD
CY2014Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	90000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	16000	USD
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	ibio	Earnings From Reversal Of Expenses EarningsFromReversalOfExpenses	1900000	USD
CY2015Q4	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	78000	USD
CY2014Q4	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	78000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	IBIO
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82609410	shares

Files In Submission

Name	View Source	Status
0001144204-16-083497-index-headers.html	Edgar Link	pending
0001144204-16-083497-index.html	Edgar Link	pending
0001144204-16-083497.txt	Edgar Link	pending
0001144204-16-083497-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ibio-20151231.xml	Edgar Link	completed
ibio-20151231.xsd	Edgar Link	pending
ibio-20151231_cal.xml	Edgar Link	unprocessable
ibio-20151231_def.xml	Edgar Link	unprocessable
ibio-20151231_lab.xml	Edgar Link	unprocessable
ibio-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v430583_10q.htm	Edgar Link	pending
v430583_ex10-3.htm	Edgar Link	pending
v430583_ex10-4.htm	Edgar Link	pending
v430583_ex10-5.htm	Edgar Link	pending
v430583_ex31-1.htm	Edgar Link	pending
v430583_ex31-2.htm	Edgar Link	pending
v430583_ex32-1.htm	Edgar Link	pending
v430583_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2016 Q1 Form 10-Q Financial Statement

#000114420416083497 Filed on February 22, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2016 Q1 Form 10-Q Financial Statement

#000114420416083497 Filed on February 22, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio